Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3577 Comments
849 Likes
1
{用户名称}
Elite Member
2 hours ago
{协议答案}
👍 60
Reply
2
{用户名称}
Registered User
5 hours ago
{协议答案}
👍 189
Reply
3
{用户名称}
Loyal User
1 day ago
{协议答案}
👍 236
Reply
4
{用户名称}
Regular Reader
1 day ago
{协议答案}
👍 193
Reply
5
{用户名称}
Experienced Member
2 days ago
{协议答案}
👍 162
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.